Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681790 | 0.93 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3803130 | 0.93 | ACHE (0.36) | ACHEPGRNR3C2ARJAK2 | |
| SCHEMBL3647479 | 0.82 | ACHE (0.38) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL3975536 | 0.82 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3639432 | 0.80 | ACHE (0.37) | ACHEADRA2AADRA2BPGRNR3C2 | |
| SCHEMBL3975549 | 0.80 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3971413 | 0.79 | BRD4 (0.36) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3638329 | 0.79 | ACHE (0.38) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL4083212 | 0.79 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3681193 | 0.78 | ACHE (0.38) | ACHEADRA2AADRA2BJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232307-B2 | Indane-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-07-31 | — | — | US | disclosed |
| US-20110053980-A1 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| EP-2011786-A1 | Indane-amine derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053980-A1 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | INMT, IDO1, PNMT | ACHE 60/4885ADRA2A 32/4885ADRA2B 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.